The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model.
Linda Heijmen
No relevant relationships to disclose
Otto C. Boerman
No relevant relationships to disclose
Cornelis J. A. Punt
No relevant relationships to disclose
E. Ter Voert
No relevant relationships to disclose
Wim J.G. Oyen
No relevant relationships to disclose
Jan Bussink
No relevant relationships to disclose
Fred C.G.J. Sweep
No relevant relationships to disclose
Peter Laverman
No relevant relationships to disclose
Paul Span
No relevant relationships to disclose
Lioe-Fee de Geus- Oei
No relevant relationships to disclose
Arend Heerschap
No relevant relationships to disclose
Hanneke W.M. Van Laarhoven
No relevant relationships to disclose